Brief: Cognition Therapeutics To Present Preclinical Results Demonstrating Therapeutic Potential For Sigma-2 Receptor Modulators In Dry Age-Related Macular Degeneration
25/04/2022 21:06
April 25 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS TO PRESENT PRECLINICAL RESULTS
DEMONSTRATING THERAPEUTIC POTENTIAL FOR SIGMA-2 RECEPTOR
MODULATORS IN DRY AGE-RELATED MACULAR DEGENERATION
* COGNITION THERAPEUTICS INC- PLANS TO INITIATE A PHASE 2
CLINICAL
STUDY FOR CT1812, COMPANY'S LEAD Σ-2 RECEPTOR MODULATOR, IN
PATIENTS WITH DRY AMD
Source text for Eikon: ID:nGNX21DHht
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB